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ABBREVIATIONS 
ADEM Acute disseminated encephalomyelitis 
ADS  Acquired demyelinating syndromes 
EDSS  Expanded Disability Status Scale 
MOG  Myelin oligodendrocyte glycoprotein 
 
[Abstract]  
AIM To review the demographics and clinical and paraclinical parameters of children 
with myelin oligodendrocyte glycoprotein (MOG) antibody-associated relapsing 
disease. 
METHOD In this UK-based, multicentre study, 31 children with MOG antibody-
associated relapsing disease were studied retrospectively.  
RESULTS Of the 31 children studied, 14 presented with acute disseminated 
encephalomyelitis (ADEM); they were younger (mean 4.1 years) than the remainder 
(mean 8.5 years) who presented with optic neuritis and/or transverse myelitis 
(p<0.001). Similarly, children who had an abnormal brain magnetic resonance 
imaging (MRI) at onset (n=20) were younger than patients with normal MRI at onset 
(p=0.001) or at follow-up (p<0.001). ‘Leukodystrophy-like’ MRI patterns of 
confluent largely symmetrical lesions was seen during the course of the disease in 7 
out of 14 children with a diagnosis of ADEM, and was only seen in children younger 
than 7 years of age. Their disability after a 3-year follow-up was mild to moderate, 
and most patients continued to relapse, despite disease-modifying treatments.  
INTERPRETATION MOG antibody should be tested in children presenting with 
relapsing neurological disorders associated with confluent, bilateral white matter 
changes, and distinct enhancement pattern. Children with MOG antibody-associated 
disease present with age-related differences in phenotypes, with a severe 
leukoencephalopathy phenotype in the very young and normal intracranial MRI in the 
older children. This finding suggests a susceptibility of the very young and 
myelinating brain to MOG antibody-mediated mechanisms of damage. 
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What this paper adds  
• Myelin oligodendrocyte glycoprotein (MOG) antibody-associated 
demyelination manifest with an age-related phenotype. 
• Children with MOG antibody and leukodystrophy-like imaging patterns tend 
to have poor response to second line immunotherapy. 
 
There is growing evidence that a diagnosis of myelin oligodendrocyte glycoprotein 
(MOG) antibody-associated disease can be made in children with relapsing acquired 
demyelinating syndromes (ADS) whose sera are positive for MOG antibody.
1,2
 
Previous studies have detected MOG antibody both at first presentation and at time of 
a relapse in children with ADS.3–6 In a recent, multicentre study, we detected MOG 
antibody in 83% of children with the phenotype of aquaporin-4 antibody-negative 
neuromyelitis optica spectrum disorder and 100% of patients originally diagnosed 
with multiphasic disseminated encephalomyelitis.
1
 Children with MOG antibody-
associated disease were, overall, young (median age 6y), mainly female, and mainly 
presented with either optic neuritis with visual disturbance or acute disseminated 
encephalomyelitis (ADEM) with encephalopathy, motor deficits, seizures, and 
cerebellar symptoms.1 
Clinical and imaging patterns of ADS may share features with some inherited 
conditions such as mitochondrial disorders, X-linked Charcot–Marie–Tooth, 
mucopolysaccharidoses, galactosaemia, and L-2-hydroxyglutaric aciduria.
7
 These 
differential diagnoses are most frequently suspected in children presenting with 
ADEM,8 and more so when the disease becomes more chronic with recurrent relapses 

































































and progressive disabilities.8 Magnetic resonance imaging (MRI) is felt to distinguish 
between the leukodystrophies and the acquired leukoencephalopathies. In very young 
children with leukodystrophies, brain MRI typically shows confluent and bilateral, 
essentially symmetric, white matter abnormalities.
7
 Although contrast enhancement 
may support an acquired condition this can also be found in genetically defined white 
matter disorders.9 Conversely, children with ADEM usually show multifocal and 
asymmetric white matter abnormalities on MRI.7 In our previous study,1 we found 
that patients with MOG antibody-associated disease can share clinical and MRI 
similarities with leukodystrophies. 
The aim of this study was to examine whether there were age-related 
differences in MOG antibody-associated disease phenotypes, with an emphasis on the 
leukodystrophy-like pattern.  
 
METHOD 
In this retrospective study, we collected data from 31 participants attending three 
centres of the UK and Ireland Childhood CNS Inflammatory Demyelination Working 
Group: Great Ormond Street Hospital (London), Evelina London Children Hospital, 
and Birmingham Children Hospital; 26 cases have been included in a previous study 
and an additional five cases were studied.1 All children had (1) a diagnosis of ADS, 
defined as two or more episodes of acquired central nervous system demyelinating 
events characterized by deficits persisting for at least 24 hours and involving the optic 
nerve, brain, or spinal cord, and associated with focal T2 abnormalities on brain 
and/or spinal cord MRI; (2) presence of MOG antibody detected either at onset or at 
the time of a clinical relapse, using live cell-based assays9; (3) (at onset) were younger 
than 18 years of age.  
Demographic characteristics and clinical information on type of presentation, 
disability at onset (as measured by the Expanded Disability Status Scale [EDSS]), 
disease-modifying treatments, and number of relapses over time were collected. 
Outcomes at last follow-up were retrieved from the patients’ medical records to 
represent the most contemporary assessment of disability (stratified to cognitive, 
motor, visual defects, and seizures). If unavailable, the information was obtained 
directly from the patient’s primary treating physician. EDSS results were documented 
at point of disease stability at least 3 months from acute or relapsing events.  
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 The brain and spinal cord MRI scans of the 31 children were reviewed (FB) 
and the following three patterns (in order of frequency) were identified, as previously 
described
1
: (1) multifocal, hazy/poorly marginated lesions involving both the grey and 
white matter; (2) spinal cord and/or optic nerve involvement with normal intracranial 
appearance or non-specific white matter lesions; (3) extensive and confluent white 
matter abnormalities, with a largely symmetric distribution, resembling a 
‘leukodystrophy-like’ MRI pattern.  
Statistical analysis was performed using commercially available software 
GraphPad Prism 6 (GraphPad, La Jolla, CA, USA). The differences in age between 
MOG antibody-positive children presenting with ADEM and those presenting with 
optic neuritis and/or transverse myelitis, and between children with abnormal MRI 
and those with normal MRI were tested using the Mann–Whitney U test. The 
difference in age between the three imaging patterns, was investigated using the 
Kruskal–Wallis test. The differences in clinical and MRI characteristics between 
children with ‘leukodystrophy-like’ phenotype and the remaining cases were explored 
using Fisher’s exact test. 
This study was approved by Great Ormond Street Hospital Research and 
Development Department (reference: 16NC10).  
 
RESULTS 
The clinical and radiological characteristics of patients with MOG antibody-
associated disease, followed-up for a median of 4 years, are shown in Table I.  
Fourteen children presented with ADEM; they were younger than the 
remainder, who presented with optic neuritis and/or transverse myelitis (mean 
4.1[1.9]y vs 8.5[3.3]y; p<0.001). Similarly, children who had an abnormal brain MRI 
were younger than patients with normal brain MRI at onset (n=20; mean age 4.6[2.8]y 
vs 8.5[3.0]y; p=0.001) and at follow-up (mean age 4.8[2.6]y vs 9.5[2.7]y; p<0.001) 
(Fig. S1, online supporting information). The most common MRI pattern at onset was 
that of multifocal, hazy/poorly marginated lesions involving both grey and white 
matter, and the least common pattern at onset was the ‘leukodystrophy-like’ MRI 
pattern (Table I). Over the course of the disease, seven children developed a 
‘leukodystrophy-like’ pattern on MRI. 
All patients showed a moderately active disease with a median annual relapse 
rate of 1, despite treatment with disease-modifying drugs in 12 children. All patients 
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with abnormal MRI at onset showed a significant (although not complete) resolution 
of lesions at follow-up. Nevertheless, despite low disability levels (measured by the 
EDSS) at follow-up (Table I), one-third (n=10) had ongoing cognitive problems.  
 
Age-related differences in phenotypes 
When the association between age and imaging patterns was examined, a 
‘leukodystrophy-like’ pattern was seen more frequently in the youngest patients 
(mean age at onset 3.7[1.3]y, range 1.8–6y), whereas an MRI pattern of multifocal, 
hazy/poorly marginated lesions, involving both grey and white matter was seen in the 
middle age group (5.2[1.9]y). Isolated spinal cord and/or optic nerve involvement 
(with normal and/or non-specific white matter lesions on MRI) was seen in the oldest 
group (9.8[2.8]y; p=0.001) (Fig. 1).  
 
‘Leukodystrophy-like’ phenotype  
Examples of the clinical and radiological patterns of leukodystrophy-like lesions in 
MOG antibody-positive children are shown in Figure 2 and Table II. A summary of 
the cases can be found in Appendix S1 (online supporting information) together with 
serial imaging of all patients (Fig. S2, online supporting information). 
All children with the ‘leukodystrophy-like’ lesions were given a diagnosis of 
ADEM at presentation. The patients presented with encephalopathy (n=7), ataxia 
(n=7), optic neuritis (n=5), and/or seizures (n=3) at presentation or relapse. The final 
diagnosis was ADEM for cases 1 to 6, and negative neuromyelitis optica spectrum 
disorder for case 7. All patients showed clinical improvement after acute treatment 
with steroids, but, overall, the outcome was poor. Four patients continued to relapse 
despite treatment with disease-modifying drugs. 
When we compared the clinical characteristics of the patients with 
‘leukodystrophy-like’ MRI pattern with the remainder of the patients with MOG 
antibody, we found that patients with this phenotype showed a worse overall outcome 
at follow-up than the other patients (median EDSS 3[range 1–5] vs median EDSS 0; 
p=0.001). However, there was no difference in the total number of relapses between 
the ‘leukodystrophy-like’ phenotype and the rest of the group.  
 
DISCUSSION 
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MOG antibody disease is increasingly recognized, but the full range of clinical 
phenotypes is not yet clear. In this study we describe an unexpected phenotype, not 
easily distinguished from that of genetic or metabolic leukodystrophies, in seven 
paediatric patients under the age of 7 years. The children presented with relapsing 
neurological syndromes associated with a ‘leukodystrophy-like’ imaging pattern that 
emerged over time. These children showed a good response to treatment with 
steroids, but four continued to relapse on conventional multiple sclerosis treatments, 
and only showed a partial response to second-line immunotherapy with azathioprine 
and mycophenolate mofetil. Persistent cognitive and behavioural problems were seen 
in four and ongoing seizures in three of these children. In these patients, MRI findings 
of predominantly confluent, bilateral white matter changes raised the differential 
diagnosis of a leukodystrophy. Interestingly, the MRI abnormalities did not always 
correlate with the clinical state of the child. Furthermore, the highly contrast-
enhancing lesions and the dramatic resolution on follow-up scans, early in the course 
of the disease, supported a diagnosis of a neuroinflammatory leukoencephalopathy.  
This study demonstrates that clinical and radiological heterogeneity in MOG 
antibody-associated phenotypes is age dependent, with the youngest children 
presenting preferentially with extensive brain involvement and older children (and 
adults)10 predominantly with optic neuritis and normal intracranial imaging. This is 
consistent with the evidence for more profound and severe white matter abnormalities 
in the early-onset and severely affected patients with leukodystrophies, such as 
DARS2,
11
 than patients with late-onset and mild leukodystrophies.
12
  
The finding of a ‘leukodystrophy-like’ phenotype in young children may 
reflect susceptibility of the myelinating brain to MOG antibody-mediated disease. In 
rat studies, expression of MOG occurred after the initiation of myelination, from 
postnatal day 1 onwards.
13
 MOG was detected primarily at the extracellular surface of 
myelin sheaths and oligodendrocytes, and only at low levels in the lamellae of 
compacted myelin and the myelin/axon border zone.
13,14
 Whether expression of MOG 
on the lamella surface persists into adult life is unclear. It is plausible that the 
expression decreases as myelination proceeds and is much lower in the older 
children.
15
 In addition, the myelinating brain may be more susceptible to MOG 
antibody disease caused by MOG expression on uncompacted myelin, with resulting 
immune-mediated damage and axonal loss.
16
 Such factors may contribute to 
qualitative and quantitative differences in the imaging findings in younger children 

































































with demyelination and the poorer outcome seen in this group. The reduced 
susceptibility in the fully myelinated adult brain is consistent with the overall benign 
phenotype in adult cases of MOG antibody-negative neuromyelitis optica spectrum 
disorder.
17–19
 In a cohort of 56 adults with MOG antibody, the clinical course was 
favourable, with good clinical outcomes and minimal residual disability.20 
Although only 2 out of 7 patients with ‘leukodystrophy-like’ phenotype 
demonstrated these radiological features at onset it is possible that the MRI was not 
performed at nadir or that there is a lag between clinical and radiological features. 
Alternatively, progressive loss of tissue integrity over time, leading to increasing 
neuroaxonal injury, may explain the diffuse acquired white matter injury, the poor 
cognitive outcome seen in this group, and the reduced response to immunotherapy 
over time. As seen in patients with genetic white matter disorders, MOG antibody-
positive patients with a ‘leukodystrophy-like’ MRI pattern showed a worse outcome 
at follow-up than older patients. The EDSS, which is used to assess disabilities in 
demyelinating conditions, is more heavily weighted towards motor disabilities than 
cognitive disabilities; this may explain the overall low scores seen in the cohort with 
MOG antibody-associated disease in general. Cognitive problems were seen in half of 
the children with abnormal MRI and were not reported in children with normal brain 
MRI. This finding is in keeping with recent studies observing perturbation of white 
matter trajectories and reduced age-expected brain growth (driven via reduced white 
matter growth) in children after a single episode of ADS with brain lesions.
21,22
  
Taken together, the physiological processes occurring during brain maturation 
(including increased axonal size with more efficient axonal transport, and myelin 
maturation and compaction) might explain the heterogeneity of MOG antibody 
phenotype, with a more severe leukoencephalopathy phenotype in the very young. 
Further studies into the exact pathobiological disease processes may result in better 
treatments and improved outcome in this distinct group of patients.  
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Appendix S1: Leukodystrophy-like phenotype – case summaries. 
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Table I: Characteristics of patients with myelin oligodendrocyte glycoprotein 
antibody-associated disease (n=31) 
Mean(SD) age at presentation (y:mo) 6:6(3:5.3) 
Female:male ratio 1:1.6 
Median(IQR) length of follow-up (from first clinical 
presentation) (y) 
4(3–7) 
Median(IQR) time to first relapse (mo) 4.5(3.1–8.1) 
Median(range) EDSS at last visit  1(0–5) 
Original RDS diagnoses 
NMOSD without AQP4 antibody 16(52) 
Multiphasic disseminated encephalomyelitis  9(29) 
Recurrent optic neuritis  4(13) 
ADEM-ON  2(6) 
MRI patterns at onset  
MRI abnormalities in the optic nerve and/or spinal 
cord 
17(55) 
Multifocal, poorly marginated lesions involving both 
grey and white matter  
12(39) 
Leukodystrophy-like MRI  2(6) 
MRI pattern during the disease course 
MRI abnormalities in the optic nerve and/or spinal 
cord 
11(35) 
Multifocal, poorly marginated lesions involving both 
grey and white matter 
13(42) 
Leukodystrophy-like MRI  7(23) 
Data are n(%) unless otherwise indicated. IQR, interquartile range; EDSS, Expanded 
Disability Status Scale; RDS, relapsing demyelinating syndrome; NMOSD, 
neuromyelitis optica spectrum disorder; AQP4, aquaporin-4; ADEM-ON, acute 
disseminated encephalomyelitis followed by optic neuritis; MRI, magnetic resonance 
imaging. 
 

































































Table II: Clinical, radiological, serological, and cerebrospinal fluid results; treatment; 
and clinical outcome of seven children with myelin oligodendrocyte glycoprotein 
antibody and ‘leukodystrophy-like’ phenotype
















































































with ataxia and 





Multiple relapses with 
ataxia and cognitive 
regression evolving 
pyramidal signs lower 
limbs and bulbar 
dysfunction (3/y) over 8y 









2 F 4 White MDE
M 
Behavioural 
change, ataxia, and 
bilateral sixth nerve 




NT Multiple relapses at 9–
12mo intervals 
characterized by altered 
behaviour, loss of balance, 
weakness (left more than 
right), and slurred speech 
over 10y 
On AZA for 3y, 





















Encephalopathy with ataxia 
and right-sided hemiplegia  
Not on treatment  Clinical 
recovery but 
still early  
1.5 

































































ataxia, and a tremor 
4 F 5 White MDE
M 
Encephalopathy, 
ataxia, and right 







seizure and ataxia and optic 
neuritis; 9–10 relapses with 
similar symptomatology 
over a 6y period with 
longest interattack period of 
2y 
No response to 
IFN-β and AZA; 
commenced on 
natalizumab at 
10y with no 









5 F 2 White MDE
M 
Encephalopathy 






5 clinical relapses with 
similar symptomatology  
Reduction of 
ARR on MMF 



















Two relapses with similar 
symptomatology 5 and 7y 
after initial presentation 
with encephalopathy and 
cerebellar signs; during the 
second episode developed 
optic neuritis 






















































































NT Left optic neuritis and 
longitudinally extending 
transverse myelitis  
Treated with 
steroids acutely 










Patients 1 and 5 presented with leukodystrophy-like imaging characteristics at first presentation. TTFR, time to first relapse; OCB, oligoclonal 
bands; EBV, Epstein–Barr virus; EDSS, Expanded Disability Status Scale; M, male; MDEM, multiphasic disseminated encephalomyelitis; IFN, 
interferon; AZA, azathioprine; F, female; NT, not tested; AED, antiepileptic drugs; ARR, annual relapse rate; MMF, mycophenolate mofetil; 
NMOSD, neuromyelitis optica spectrum disorder. 
 
  

































































Figure 1: Association between age at onset and magnetic resonance imaging patterns in myelin oligodendrocyte glycoprotein antibody-
associated disease. The box-plot (showing median and interquartile range) demonstrates the relationship between the predominant imaging 
pattern and the age group. The leukodystrophy-like pattern was predominantly seen in (a) younger children; (b) confluent, hazy/poorly 
marginated lesions involving both grey and white matter were seen in the middle-age group; (c) the spinal cord/optic nerve (ON) involvement 
with normal or non-specific brain imaging was seen in the older group. TM, transverse myelitis. 
 
Figure 2: Examples of patients with myelin oligodendrocyte glycoprotein (MOG) antibody with a leukodystrophy-like magnetic resonance 
imaging (MRI) pattern. (a) Radiological progression in patient 1 (top row). Age 2y at first presentation with encephalopathy, the MRI changes 
were predominantly in the grey matter of the basal ganglia and thalami. At clinical relapse 16mo later, there was similar symptomatology with 
near complete resolution of the previously signal abnormalities. Follow-up imaging when clinically improving 2mo later (18mo from onset) 
demonstrated confluent bilateral predominantly subcortical diffuse white matter changes, more posteriorly, with extensive nodular enhancement. 
There was significant resolution on follow-up scans 3mo later. (b) Radiological progression in patient 2 (second row). Age 20mo, at first 
presentation, there were confluent white matter lesions in the thalami and pons. Repeat imaging during the acute presentation (day 14), when still 
symptomatic, demonstrated expansion of the lesions with new cerebellar peduncle lesions and optic track involvement (not shown). Imaging at 
the time of clinical relapse 4mo later, demonstrated confluent bilateral predominantly subcortical diffuse white matter changes with extensive 
nodular enhancement. (c) MRI patterns observed in MOG antibody-positive patients with inflammatory leukoencephalopathy.  
 
Comment [JM9]: TYPESETTER: Please fix 
the typo in Figure 1, y-axis to (years). 



































































Figure 1  
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Figure 2  
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Supplemental figure 1  
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Leukodystrophy-like phenotype – case summaries  
 
Case 1: A 6 year-old boy presented with recurrent episodes of ataxia and progressive deterioration in gait over 
8 months. MRI revealed subcortical white matter changes in the left temporal lobe, pons and cerebellar. He was 
treated with IV steroids and prolonged oral prednisolone course followed by interferon (1 year) but continued to 
deteriorate with worsening ataxia, evolving pyramidal signs in the lower limbs, and bulbar dysfunction. He has 
been clinically stable on Azathioprine and has not suffer any further deterioration he remains severely disable.  
 
Case 2: A 4-years old girl presented with behavioural change, ataxia and a 6th nerve palsy following a febrile 
illness. MRI revealed confluent bilateral white matter changes. She relapsed 4 months later with a similar 
encephalopathy. Subsequent episodes occurred at 9 to 12 month intervals, characterised by altered behaviour, 
loss of balance, weakness (left more than right), and slurred speech. She was commenced on Azathioprine but 
continued to relapse. Azathioprine was therefore stopped after 3 years and she is currently on no treatment.. 
She has a left hemiparesis and mild learning difficulties.  
 
Case 3: A 20-months old girl presented with encephalopathy, fluctuating drowsiness and irritability, intermittent 
squint, ataxia and tremor. MRI revealed predominantly grey matter involvement in the thalami and she was 
treated for viral encephalitis with no clinical improvement. Repeat scan at day 14, while still symptomatic, 
revealed some resolution of the thalamic lesions but new lesions in the pons and the middle cerebellar 
peduncle. She had a good response to steroids but relapsed at 4 months with similar symptoms to the initial 
presentation. She received a prolonged steroid weaning course and remained relapse free at follow-up one year 
after her second episode. 
 
Case 4: A 5-year-old girl presented with a right-sided focal seizure while overseas. She was treated for 
encephalitis, and recovered. Three weeks later she developed fevers, joint pains and had a second seizure. 
MRI revealed cortical white matter changes and she was treated with steroids. She had a further relapse with 
ataxia and encephalopathy requiring steroids. She went on to have ten relapses over the next six years, with 
recurrent optic neuritis, dysarthric speech and further seizures. She was subsequently treated with further 
courses of steroids, azathioprine and interferon, and is currently on Natalizumab.  
 
Case 5: A 2 year-old girl presented with subacute encephalopathy with irritability and intermittent temperatures. 
MRI revealed bilateral basal ganglia changes.  She was treated with steroids and IVIG with a good response. 
She suffered a further clinical relapse 15 months later with similar symptomatology.  MRI revealed extensive, 
bilateral diffuse white matter signal change. She was treated with IVIG and mycophenolate mofetil (MMF) but 
continued to relapse.  
 
Case 6: A 5-year-old boy, with mild global delay and autistic spectrum disorder, presented with subacute onset 
































































encephalopathy with intermittent fevers, headaches and lower limb weakness associated with falls. MRI 
revealed extensive signal changes involving cortical and subcortical white matter and thalamic changes 
bilaterally. CSF was negative with no OCB and he was diagnosed with ADEM but received no treatment. He 
recovered from his acute episode but remains developmentally delayed. He suffered a similar clinical and 
radiological relapse with additional optic neuritis 6 years later and was treated with 3 days of intravenous methyl 
prednisolone followed by oral prednisolone.  
 
Case 7: A 2 years and 10 month-old girl presented with fever, slurred speech and unsteady gait. MRI revealed 
extensive white matter changes, with confluent diffuse areas of abnormal signal in the cerebral white matter, 
cerebellar white matter and brain stem. She made a gradual recovery but the left divergent squint persisted. A 
few months later she developed focal seizures. At 8 years of age her squint became more apparent, her vision 
deteriorated and she developed a right-sided foot drop. She went on to develop left leg weakness and urinary 
incontinence. She was treated with steroids with good response.  
 
 
Supplementary Figure legends 
 
Figure S1: Box plots showing the median and interquartile range. (a) Patients presenting with acute 
disseminated encephalomyelitis were younger than children presenting with optic neuritis or transverse myelitis 
(n=17; p<0.001). Children with a normal brain magnetic resonance imaging at (b) presentation and (c) 
throughout the disease course were older than those with abnormal intracranial magnetic resonance imaging 
(p=0.001 and p<0.001, respectively). 
Figure S2: Serial imaging at follow-up of the seven index cases using axial T2-weighted sequences shows brain 
parenchymal changes in the supratentorial and infratentorial compartments. Case 1: the initial changes were in 
the internal and external capsular areas with involvement of the basal ganglia, thalami, and pons. On follow-up, 
bilateral confluent deep and subcortical white matter changes were noted in both cerebral hemispheres. Over 
time, these changes showed partial resolution accompanied by brain parenchymal volume loss, and the hind 
brain changes became more limited to the cerebello-pontine regions. Case 2: extensive bilateral cerebral white 
matter signal abnormality was noted with incomplete resolution on later scans. The initial changes in the 
cerebello-pontine angles resolved over time. Case 3: the initial changes in the thalami and brainstem evolved 
into a leukodystrophy-like pattern within 4 months. Case 4: the pattern of white matter involvement is diffuse but 
asymmetric, changing predominantly to the contralateral side over time with ensuing brain atrophy. Case 5: 
There was initial involvement of the basal ganglia and thalami but more symmetric white matter changes in both 
cerebral hemispheres on follow-up imaging. Case 6: extensive, rather symmetric white matter signal abnormality 
in both cerebral hemispheres and cerebello-pontine angles was followed by partial resolution of the cerebral 
changes over time. Case 7: early scans showed extensive subcortical white matter involvement and patchy hind 
brain changes, again localized to the cerebello-pontine regions, with gradual partial resolution over time. 
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